Rodolfo F. Perini
About
Rodolfo F. Perini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Rodolfo F. Perini has authored 144 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Pulmonary and Respiratory Medicine, 85 papers in Oncology and 47 papers in Cancer Research. Recurrent topics in Rodolfo F. Perini's work include Renal cell carcinoma treatment (90 papers), Cancer Immunotherapy and Biomarkers (65 papers) and Bladder and Urothelial Cancer Treatments (35 papers). Rodolfo F. Perini is often cited by papers focused on Renal cell carcinoma treatment (90 papers), Cancer Immunotherapy and Biomarkers (65 papers) and Bladder and Urothelial Cancer Treatments (35 papers). Rodolfo F. Perini collaborates with scholars based in United States, United Kingdom and Spain. Rodolfo F. Perini's co-authors include Joaquim Bellmunt, Dean F. Bajorin, Ronald de Wit, Toni K. Choueiri, Jae‐Lyun Lee, David J. Vaughn, Howard Gurney, Nicholas J. Vogelzang, Lawrence Fong and Yves Fradet and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.
In The Last Decade
Rodolfo F. Perini
135 papers receiving 6.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Rodolfo F. Perini United States | 26 | 4.0k | 3.1k | 2.0k | 1.2k | 852 | 144 | 6.1k | ||
| Miguel Ángel Climent Spain | 18 | 3.5k 0.9× | 2.0k 0.6× | 1.4k 0.7× | 839 0.7× | 526 0.6× | 84 | 5.2k | ||
| Thomas Powles United Kingdom | 24 | 2.4k 0.6× | 1.9k 0.6× | 1.1k 0.5× | 649 0.5× | 558 0.7× | 105 | 3.7k | ||
| Christian Poehlein United States | 22 | 2.7k 0.7× | 1.6k 0.5× | 1.2k 0.6× | 559 0.5× | 1.1k 1.3× | 79 | 3.8k | ||
| Saby George United States | 30 | 3.3k 0.8× | 939 0.3× | 2.8k 1.4× | 1.4k 1.1× | 692 0.8× | 170 | 5.0k | ||
| Bradley A. McGregor United States | 27 | 1.8k 0.4× | 1.2k 0.4× | 1.4k 0.7× | 782 0.6× | 270 0.3× | 176 | 3.2k | ||
| Xavier García del Muro Spain | 35 | 1.7k 0.4× | 1.9k 0.6× | 3.2k 1.6× | 1.9k 1.5× | 173 0.2× | 186 | 5.3k | ||
| Lisa Sengeløv Denmark | 19 | 1.4k 0.4× | 2.1k 0.7× | 1.1k 0.5× | 581 0.5× | 303 0.4× | 45 | 3.5k | ||
| Arlene O. Siefker‐Radtke United States | 49 | 3.7k 0.9× | 7.3k 2.3× | 2.0k 1.0× | 2.7k 2.2× | 743 0.9× | 229 | 9.9k | ||
| Dimitrios Bafaloukos Greece | 34 | 3.0k 0.7× | 585 0.2× | 1.6k 0.8× | 1.2k 1.0× | 551 0.6× | 132 | 4.5k | ||
| Jean Hoffman‐Censits United States | 24 | 1.2k 0.3× | 2.4k 0.8× | 919 0.4× | 870 0.7× | 249 0.3× | 153 | 3.4k |
Countries citing papers authored by Rodolfo F. Perini
Since
Specialization
Citations
This map shows the geographic impact of Rodolfo F. Perini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rodolfo F. Perini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rodolfo F. Perini more than expected).
Fields of papers citing papers by Rodolfo F. Perini
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Rodolfo F. Perini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rodolfo F. Perini. The network helps show where Rodolfo F. Perini may publish in the future.
Co-authorship network of co-authors of Rodolfo F. Perini
This figure shows the co-authorship network connecting the top 25 collaborators of Rodolfo F. Perini. A scholar is included among the top collaborators of Rodolfo F. Perini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rodolfo F. Perini. Rodolfo F. Perini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Choueiri, Toni K., Todd M. Bauer, Jaime R. Merchan, et al.. (2025). Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 43(5_suppl). 549–549.
2.
Kondoh, Chihiro, Woo Kyun Bae, Satoshi Tamada, et al.. (2025). First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia. Japanese Journal of Clinical Oncology. 55(4). 406–413.
3.
Strowd, Roy E., Macarena de la Fuente, Todd M. Bauer, et al.. (2025). Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: results of the glioblastoma expansion cohort. Neuro-Oncology Advances.
4.
Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2024). Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 42(16_suppl). 4505–4505.
5.
Else, Tobias, Eric Jonasch, Othon Iliopoulos, et al.. (2024). Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clinical Cancer Research. 30(9). 1750–1757.
6.
Brugarolas, James, Pooja Ghatalia, S. George, et al.. (2023). 1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study. Annals of Oncology. 34. S1011–S1011.
7.
Jonasch, Eric, Todd M. Bauer, Kyriakos P. Papadopoulos, et al.. (2023). Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. European Journal of Cancer. 196. 113434–113434.
8.
Motzer, Robert J., Manuela Schmidinger, Masatoshi Eto, et al.. (2023). LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncology. 19(2). 113–121.
9.
McDermott, David F., Avivit Peer, Neeraj Agarwal, et al.. (2023). LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma. The Oncologist. 28(Supplement_1). S11–S11.
10.
Shah, Neil J., et al.. (2023). Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab. Urologic Oncology Seminars and Original Investigations. 41(11). 459.e1–459.e8.
11.
Narayan, Vivek, Othon Iliopoulos, Benjamin L. Maughan, et al.. (2023). SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY. Neuro-Oncology Advances. 5(Supplement_3). iii31–iii31.
12.
Choueiri, Toni K., Todd M. Bauer, Jaime R. Merchan, et al.. (2023). LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC). Annals of Oncology. 34. S1328–S1329.
13.
McDermott, David F., Jae‐Lyun Lee, Georg A. Bjarnason, et al.. (2021). Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 39(9). 1020–1028.
14.
McDermott, David F., Jae‐Lyun Lee, Marek Ziobro, et al.. (2021). Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 39(9). 1029–1039.
15.
Wiley, Henry E., Hanna R. Coleman, Eric Jonasch, et al.. (2021). Oral HIF-2α inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease. Investigative Ophthalmology & Visual Science. 62(8). 32–32.
16.
Kondoh, Chihiro, Woo Kyun Bae, Satoshi Tamada, et al.. (2020). 200O Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia. Annals of Oncology. 31. S1319–S1319.
17.
McGovern, Ian, et al.. (2019). PCN45 PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS OTHER FIRST-LINE (1L) SYSTEMIC THERAPIES FOR ADVANCED/METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCMRCC) — A NETWORK META-ANALYSIS (NMA). Value in Health. 22. S444–S444.
18.
Atkins, Michael B., F. Stephen Hodi, John A. Thompson, et al.. (2018). Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clinical Cancer Research. 24(8). 1805–1815.
19.
Ayers, Mark, Michael Nebozhyn, Răzvan Cristescu, et al.. (2018). Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy. Clinical Cancer Research. 25(5). 1564–1573.
20.
Petrylak, Daniel P., Nicholas J. Vogelzang, Yves Fradet, et al.. (2017). Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc). Annals of Oncology. 28. v298–v298.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Miguel Ángel Climent Breakdown of academic impact, for papers by Thomas Powles Breakdown of academic impact, for papers by Christian Poehlein Breakdown of academic impact, for papers by Saby George Breakdown of academic impact, for papers by Bradley A. McGregor Breakdown of academic impact, for papers by Xavier García del Muro Breakdown of academic impact, for papers by Lisa Sengeløv Breakdown of academic impact, for papers by Arlene O. Siefker‐Radtke Breakdown of academic impact, for papers by Dimitrios Bafaloukos Breakdown of academic impact, for papers by Jean Hoffman‐Censits